Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

CompletedOBSERVATIONAL

Enrollment

331,541

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions

Age-related Macular Degeneration (AMD)

Interventions

OTHER

Aflibercept

intravitreal injection

OTHER

Ranibizumab

intravitreal injection

OTHER

Bevacizumab

intravitreal injection

Trial Locations (1)

Novartis Investigative Site, East Hanover